TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05820386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin-to-skin Contact (SSC)
Description: For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incubator
Description: In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
Study: NCT05205018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing performed remotely through videocalls
Description: Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
Study: NCT05887349

Intervention type: OTHER
Group type: OTHER
Intervention: Neck Stabilization Exercise
Description: 1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercise + Rocabado Exercises
Description: 2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied.
Study: NCT06556862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 25 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
Study: NCT04740151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best PEEP
Description: In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PEEP
Description: In OLV, a PEEP of 5 cm H2O will be set.
Study: NCT05229016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
Study: NCT04808544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinalbuphine sebacate
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT05875428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
Study: NCT05229016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
Study: NCT06095804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ultrasound Jejunostomy
Description: Placement of a jejunostomy tube using the PUMA-J System
Study: NCT06451003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to clinical decision support system and education
Description: Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge.
Study: NCT04988139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individualized educational training
Description: 50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
Study: NCT06445296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat meal containing beef
Description: High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal containing Beyond Meat
Description: High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
Study: NCT06172517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthosis intervention
Description: Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
Study: NCT06353165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: product containing 0.45% stannous fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Dental Cream
Description: product containing 0.76% sodium monofluorophosphate
Study: NCT04961047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital neurotherapy (DNT) Treatment
Description: The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control group
Description: Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
Study: NCT05981157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotinib plus Tirelizumab
Description: Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study: NCT04813159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischaemic Conditioning (RIC)
Description: The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-control
Description: The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
Study: NCT05229016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflection on health-related experiences
Description: This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
Study: NCT04788108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone
Description: Dydrogesterone tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06256783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baozhu Keli
Description: Once enrolled, participants will be administrated Baozhu Keli
Study: NCT05138406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation
Description: Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
Study: NCT05542329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring by Tele-Medecine
Description: Monitoring by Tele-Medecine
Study: NCT04969042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pins Medical G122 RS
Description: G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
Study: NCT05901272

Intervention type: OTHER
Group type: OTHER
Intervention: Local clinical champion
Description: A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
Study: NCT05509153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC
Description: 1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
Study: NCT05732844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention group with Enna pelvic ball
Description: The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
Study: NCT05277688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant concurrent chemoradiotherapy
Description: concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
Study: NCT05491694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m2，IVD，q3w

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasoun
Description: HIFU treatment at lesion site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2，IVD，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5，IVD，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260mg/m2，IVD，q3w
Study: NCT05374681

Intervention type: OTHER
Group type: OTHER
Intervention: Medical treatment
Description: Medical treatment alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: Medical treatment alone

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical treatment
Description: Surgical treatment alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Surgical treatment alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embolization of the MMA
Description: The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embolization of the MMA
Description: The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
Study: NCT05463549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative video
Description: An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
Study: NCT05628779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriClip TTVr system (Abbott Vascular)
Description: Edge-to-edge leaflet approximation for the tricuspid valve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL TTVr system (Edwards Lifesciences)
Description: Edge-to-edge leaflet approximation for the tricuspid valve
Study: NCT05917028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Micro-Embolization
Description: Participants will undergo TAME with Nexsphere-F.
Study: NCT06331741

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane
Description: Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)
Description: Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity
Description: Arthroplasty with consequent collagen membrane implantation
Study: NCT05470764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets
Description: Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets
Description: Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
Study: NCT05901272

Intervention type: OTHER
Group type: OTHER
Intervention: Local clinical champion
Description: A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.

Intervention type: OTHER
Group type: OTHER
Intervention: Learning collaborative
Description: Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.

Intervention type: OTHER
Group type: OTHER
Intervention: Learning collaborative
Description: Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.